Roche said at the AMP annual meeting that it plans to commercialize the system in Europe with CE IVD marking for clinical applications and in the US with a 510(k) exemption.
The sales decline was largely due to a slowdown in productivity related to the recent launch of the company's global enterprise resource planning system in Western Europe.
The legal battle began last fall when LabCorp subsidiary Esoterix and Johns Hopkins University sued Myriad alleging infringement of four patents.
Following an inter partes review requested by 10x Genomics, the Patent Trial and Appeal Board invalidated a number of claims in a RainDance patent.
Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.
The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
The UCSF-based Blood Systems Research Institute will conduct research using RainDance's digital PCR platforms as part of a new $20 million amfAR Institute for HIV Cure Research.
The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.
The company filed to go public in March with plans to offer up to $60 million of its stock.
The company has established a streamlined workflow that customizes and automates key steps of the sample prep process.
The World Health Organization has announced the members of its gene-editing committee, according to NPR.
DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.
The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.
In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.